CHEK1 and neoplasm: Research shows that activation of the CHK1/CDK1 signaling pathway leads to NSCLC cell cycle arrest, thereby enhancing DDR capacity, attenuating cisplatin (DDP) cytotoxicity, and ultimately resulting in tumor cell resistance [48].